Publications

5891 Results

A phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for Stage IA-IIA Hodgkin's disease (SWOG 9133, CALGB 9391)

Authors
OW Press;M LeBlanc;A Lichter;TH Wasserman;J Unger;T Miller;RI Fisher
Journal / Conference
Leukemia & Lymphoma 42(Suppl.2):52(#P-089)
Year
2001
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-9133

A phase III trial of CHOP followed by Bexxar (tositumomab and Iodine-131-tositumomab) for treatment of newly diagnosed follicular non-Hodgkin's lymphomas (SWOG 9911)

Authors
OW Press;JM Unger;RM Braziel;DG Maloney;ML LeBlanc;TM Grogan;TP Miller;RI Fisher
Journal / Conference
Blood 98(11):843a-844a(#3504)
Year
2001
Research Committee(s)
Lymphoma
Study Number(s)
S9911

Dose-intense CHOPx2 therapy of intermediate grade lymphoma -- a phase II study of the Southwest Oncology Group (SWOG)

Authors
DW Blayney;M LeBlanc;RI Fisher
Journal / Conference
Blood 98(11):343a(#1448)
Year
2001
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-9349

A phase II trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkin's lymphoma: SWOG 9800

Authors
DG Maloney;OW Press;RM Braziel;JM Unger;ML LeBlanc;TM Grogan;TP Miller;RI Fisher
Journal / Conference
Blood 98(11):843a(#3502)
Year
2001
Research Committee(s)
Lymphoma
Study Number(s)
S9800

Cellular proteins determined by immunohistochemistry predict outcome in patients with aggressive non-Hodgkin's lymphoma: a first generation model of risk.

Authors
TP Miller;TM Grogan;J Unger;R Braziel;M Jaramillo;RI Fisher
Journal / Conference
Blood 98(11):125a(#526)
Year
2001
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8819

CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkins lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial.

Authors
TP Miller;M LeBlanc;C Spier;E Chase;RI Fischer
Journal / Conference
Blood 98(11):724a-725a(#3024)
Year
2001
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8736 (INT-0093)

Prognostic implication of additional cytogenetic aberrations in denovo acute myeloid leukemia (AML) with t(15:17), t(8;21) or inv(16)/t(16;16).

Authors
PH Wiernik;H Kim;H Gundacker;G Dewald;ML Slovak;E Paietta;FR Appelbaum;MS Tallman
Journal / Conference
Blood 98(11):457a(#1913)
Year
2001
Research Committee(s)
Leukemia
Study Number(s)
SWOG-9007

The significance of trisomy 8 in myeloid leukemia: a Southwest Oncology Group (SWOG) study.

Authors
ML Slovak;H Gundacker;SR Wolman;FR Appelbaum
Journal / Conference
American Journal of Human Genetics 69(4):232(#285)
Year
2001
Research Committee(s)
Leukemia
Study Number(s)
SWOG-8750, SWOG-9007, SWOG-9031, SWOG-9034 (EST-3489) (CALGB-9120), SWOG-9129 (INT-0129), SWOG-9333, SWOG-9500

Locally advanced nasopharyngeal cancer

Authors
JF Ensley;E Youseff;H Kim;G Yoo
Journal / Conference
Current Treatment Options in Oncology 2(1):15-23
Year
2001
Research Committee(s)
Head and Neck
Study Number(s)
SWOG-8892 (INT-0099) (EST-2388) (RTOG-8817)

Secondary analyis of RTOG 9310: an Intergroup phase II combined modality treatment of primary central nervous system lymphoma with chemotherapy and hyperfractionated radiotherapy

Authors
BJ Fisher;W Sieferheld;C Schultz;L De Angelis;D Nelson;SC Schold;W Curran
Journal / Conference
Int J Radiat Oncol Biol Phys 51(3):166(#297)
Year
2001
Research Committee(s)
Brain
Study Number(s)
SWOG-9310 (INT-0143) (RTOG-93-10)